Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colobreathe versus TOBI in cystic fibrosis with Pseudomonas aeruginosa infection
2004-003675-36Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cystic fibrosis (CF) and Pseudomonal infection comparing Colobreathe dry powder inhalation with TOBI nebulized inhalation (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2004; status: completed.
02
Drugs
colistimethate sodiumtobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on 2004-003675-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003675-36.